Skip to main content
. 2008 Jul 16;2008(3):CD006297. doi: 10.1002/14651858.CD006297.pub2

Comparison 7. Heterogeneity analyses.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Glycated haemoglobin‐ random effect model 22   Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Short term 4 1259 Mean Difference (IV, Random, 95% CI) ‐0.13 [‐0.33, 0.07]
1.2 Intermediate term 10 2724 Mean Difference (IV, Random, 95% CI) ‐0.17 [‐0.26, ‐0.08]
1.3 Long term 9 3302 Mean Difference (IV, Random, 95% CI) ‐0.01 [‐0.11, 0.10]
2 Fasting blood glucose‐ random effect model 17   Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Short term 4 1326 Mean Difference (IV, Random, 95% CI) ‐0.94 [‐1.32, ‐0.55]
2.2 Intermediate term 8 2015 Mean Difference (IV, Random, 95% CI) ‐1.10 [‐1.42, ‐0.78]
2.3 Long term 6 2687 Mean Difference (IV, Random, 95% CI) ‐0.88 [‐1.47, ‐0.30]
3 Fasting plasma glucose‐ random effect model 12   Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Short term 3 1208 Mean Difference (IV, Random, 95% CI) ‐1.51 [‐2.20, ‐0.81]
3.2 Intermediate term 6 2211 Mean Difference (IV, Random, 95% CI) ‐1.06 [‐1.99, ‐0.13]
3.3 Long term 4 2182 Mean Difference (IV, Random, 95% CI) ‐0.81 [‐1.60, ‐0.02]
4 Mean daily self measured blood glucose (SMBG) average (7‐8 points)‐ random effect model 6 790 Mean Difference (IV, Random, 95% CI) ‐0.33 [‐0.73, 0.07]
4.1 Short term 3 425 Mean Difference (IV, Random, 95% CI) ‐0.20 [‐0.68, 0.28]
4.2 Intermediate term 2 244 Mean Difference (IV, Random, 95% CI) ‐0.72 [‐2.97, 1.53]
4.3 Long term 1 121 Mean Difference (IV, Random, 95% CI) ‐0.5 [‐0.98, ‐0.02]
5 Fasting blood glucose‐total‐ random effect model 17 5409 Mean Difference (IV, Random, 95% CI) ‐1.01 [‐1.31, ‐0.70]
6 Fasting plasma glucose‐ total‐ random effect model 11 4868 Mean Difference (IV, Random, 95% CI) ‐1.03 [‐1.66, ‐0.41]
7 Percent of participating experiencing hypoglycemia‐ random effect model 20   Odds Ratio (M‐H, Random, 95% CI) Subtotals only
7.1 Total episodes 16 6131 Odds Ratio (M‐H, Random, 95% CI) 0.97 [0.79, 1.19]
7.2 Severe episodes 17 5827 Odds Ratio (M‐H, Random, 95% CI) 0.73 [0.61, 0.87]
7.3 Nocturnal episodes 13 5406 Odds Ratio (M‐H, Random, 95% CI) 0.67 [0.53, 0.84]
8 Hypoglycemic events per 100 patient's days‐ random effect model 19   Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 Total episodes 15 4704 Mean Difference (IV, Random, 95% CI) ‐2.42 [‐3.53, ‐1.30]
8.2 Severe episodes 15 4564 Mean Difference (IV, Random, 95% CI) 0.01 [‐0.04, 0.05]
8.3 Nocturnal episodes 17 4971 Mean Difference (IV, Random, 95% CI) ‐1.25 [‐1.63, ‐0.87]
9 Number of serious adverse events‐ random effect model 14 4878 Odds Ratio (M‐H, Random, 95% CI) 0.89 [0.65, 1.22]
10 Glycated haemoglobin‐ final values versus change from baseline 22   Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 Short term‐ final value 3 1003 Mean Difference (IV, Fixed, 95% CI) ‐0.16 [‐0.28, ‐0.04]
10.2 Short term‐ change from baseline 1 256 Mean Difference (IV, Fixed, 95% CI) 0.0 [‐0.12, 0.12]
10.3 Intermediate term‐ final value 10 2724 Mean Difference (IV, Fixed, 95% CI) ‐0.17 [‐0.23, ‐0.10]
10.4 Long term‐ final value 6 1834 Mean Difference (IV, Fixed, 95% CI) ‐0.08 [‐0.20, 0.03]
10.5 Long term‐ change from baseline 3 1468 Mean Difference (IV, Fixed, 95% CI) 0.07 [‐0.02, 0.16]
11 Fasting blood glucose‐total‐ final values versus change from baseline 17 5409 Mean Difference (IV, Fixed, 95% CI) ‐0.86 [1.00, ‐0.72]
11.1 Fasting blood glucose‐total‐ final values 13 3816 Mean Difference (IV, Fixed, 95% CI) ‐1.01 [‐1.19, ‐0.84]
11.2 Fasting blood glucose‐total‐ change from baseline 4 1593 Mean Difference (IV, Fixed, 95% CI) ‐0.60 [‐0.82, ‐0.37]
12 Fasting plasma glucose‐ total‐ final values versus change from baseline 11 4868 Mean Difference (IV, Fixed, 95% CI) ‐0.63 [‐0.86, ‐0.40]
12.1 Fasting plasma glucose‐ total‐ final values 9 3749 Mean Difference (IV, Fixed, 95% CI) ‐0.64 [‐0.89, ‐0.40]
12.2 Fasting plasma glucose‐ total‐ change from baseline 2 1119 Mean Difference (IV, Fixed, 95% CI) ‐0.53 [‐1.20, 0.13]
13 Glycated haemoglobin‐ long acting type 22 6666 Mean Difference (IV, Fixed, 95% CI) ‐0.08 [‐0.12, ‐0.04]
13.1 Glargine 12 3249 Mean Difference (IV, Fixed, 95% CI) ‐0.07 [‐0.13, ‐0.01]
13.2 Detemir 7 3095 Mean Difference (IV, Fixed, 95% CI) ‐0.11 [‐0.19, ‐0.04]
13.3 Ultralente 3 322 Mean Difference (IV, Fixed, 95% CI) 0.08 [‐0.17, 0.32]
14 Mean daily self measured blood glucose (SMBG) average (7‐8 points)‐ long acting type 6 790 Mean Difference (IV, Fixed, 95% CI) ‐0.47 [‐0.58, ‐0.36]
14.1 Glargine 4 540 Mean Difference (IV, Fixed, 95% CI) ‐0.49 [‐0.61, ‐0.38]
14.2 Detemir 1 118 Mean Difference (IV, Fixed, 95% CI) ‐0.10 [‐0.73, 0.53]
14.3 Ultralente 1 132 Mean Difference (IV, Fixed, 95% CI) 0.40 [‐0.43, 1.23]
15 Fasting blood glucose‐total‐ long acting type 17 5409 Mean Difference (IV, Fixed, 95% CI) ‐0.86 [1.00, ‐0.72]
15.1 Glargine 9 2963 Mean Difference (IV, Fixed, 95% CI) ‐0.82 [‐0.99, ‐0.65]
15.2 Detemir 6 2302 Mean Difference (IV, Fixed, 95% CI) ‐0.90 [‐1.15, ‐0.64]
15.3 Ultralente 2 144 Mean Difference (IV, Fixed, 95% CI) ‐2.17 [‐3.42, ‐0.91]
16 Fasting plasma glucose‐ total‐ long acting type 11 4868 Mean Difference (IV, Fixed, 95% CI) ‐0.63 [‐0.86, ‐0.40]
16.1 Glargine 6 2377 Mean Difference (IV, Fixed, 95% CI) ‐0.45 [‐0.73, ‐0.16]
16.2 Detemir 5 2491 Mean Difference (IV, Fixed, 95% CI) ‐0.94 [‐1.31, ‐0.57]
17 Percent of participating experiencing hypoglycemia‐ long acting type 20   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
17.1 Glargine‐ total episodes 8 2918 Odds Ratio (M‐H, Fixed, 95% CI) 0.96 [0.79, 1.17]
17.2 Glargine‐ severe episodes 10 2871 Odds Ratio (M‐H, Fixed, 95% CI) 0.76 [0.58, 0.98]
17.3 Glargine‐ nocturnal episodes 6 2311 Odds Ratio (M‐H, Fixed, 95% CI) 0.84 [0.70, 1.00]
17.4 Detemir‐ total episodes 8 3213 Odds Ratio (M‐H, Fixed, 95% CI) 0.87 [0.69, 1.11]
17.5 Detemir‐ severe episodes 7 2956 Odds Ratio (M‐H, Fixed, 95% CI) 0.70 [0.54, 0.90]
17.6 Detemir‐ nocturnal episodes 7 3095 Odds Ratio (M‐H, Fixed, 95% CI) 0.61 [0.52, 0.72]
18 Number of serious adverse events‐ long acting type 14 4878 Odds Ratio (M‐H, Fixed, 95% CI) 0.89 [0.66, 1.21]
18.1 Glargine 8 2347 Odds Ratio (M‐H, Fixed, 95% CI) 0.69 [0.46, 1.04]
18.2 Detemir 6 2531 Odds Ratio (M‐H, Fixed, 95% CI) 1.27 [0.78, 2.05]
19 Hypoglycemic events per 100 patient's days‐ long acting type 19   Mean Difference (IV, Fixed, 95% CI) Subtotals only
19.1 Glargine‐ total episodes 7 1675 Mean Difference (IV, Fixed, 95% CI) ‐0.41 [‐0.54, ‐0.27]
19.2 Glargine‐ severe episodes 7 1614 Mean Difference (IV, Fixed, 95% CI) ‐0.00 [‐0.02, 0.02]
19.3 Glargine‐ nocturnal episodes 8 1746 Mean Difference (IV, Fixed, 95% CI) ‐0.14 [‐0.21, ‐0.07]
19.4 Detemir‐ total episodes 7 2897 Mean Difference (IV, Fixed, 95% CI) ‐2.24 [‐2.51, ‐1.97]
19.5 Detemir‐ severe episodes 6 2640 Mean Difference (IV, Fixed, 95% CI) ‐0.01 [‐0.04, 0.02]
19.6 Detemir‐ nocturnal episodes 8 3213 Mean Difference (IV, Fixed, 95% CI) ‐0.89 [‐0.99, ‐0.79]
19.7 Ultralente‐ total episodes 1 132 Mean Difference (IV, Fixed, 95% CI) 0.49 [‐0.36, 1.34]
19.8 Ultralente‐ severe episodes 2 310 Mean Difference (IV, Fixed, 95% CI) 0.20 [0.08, 0.32]
19.9 Ultralente‐ nocturnal episodes 1 12 Mean Difference (IV, Fixed, 95% CI) ‐2.97 [‐4.49, ‐1.45]
20 Glycated haemoglobin‐ intermediate acting type 22 6666 Mean Difference (IV, Fixed, 95% CI) ‐0.08 [‐0.12, ‐0.04]
20.1 NPH 20 6522 Mean Difference (IV, Fixed, 95% CI) ‐0.08 [‐0.13, ‐0.04]
20.2 Lente 2 144 Mean Difference (IV, Fixed, 95% CI) ‐0.01 [‐0.53, 0.51]
21 Mean daily self measured blood glucose (SMBG) average (7‐8 points)‐ intermediate acting type 6 790 Mean Difference (IV, Fixed, 95% CI) ‐0.47 [‐0.58, ‐0.36]
21.1 NPH 5 658 Mean Difference (IV, Fixed, 95% CI) ‐0.48 [‐0.59, ‐0.37]
21.2 Lente 1 132 Mean Difference (IV, Fixed, 95% CI) 0.40 [‐0.43, 1.23]
22 Fasting blood glucose‐total‐ intermediate acting type 17 5409 Mean Difference (IV, Fixed, 95% CI) ‐0.86 [1.00, ‐0.72]
22.1 NPH 15 5265 Mean Difference (IV, Fixed, 95% CI) ‐0.84 [‐0.98, ‐0.70]
22.2 Lente 2 144 Mean Difference (IV, Fixed, 95% CI) ‐2.17 [‐3.42, ‐0.91]
23 Hypoglycemic events per 100 patient's days‐ intermediate acting type 19   Mean Difference (IV, Fixed, 95% CI) Subtotals only
23.1 NPH‐ total episodes 14 4572 Mean Difference (IV, Fixed, 95% CI) ‐0.80 [‐0.92, ‐0.68]
23.2 NPH‐ severe episodes 14 4432 Mean Difference (IV, Fixed, 95% CI) ‐0.00 [‐0.02, 0.01]
23.3 NPH‐ nocturnal episodes 16 4959 Mean Difference (IV, Fixed, 95% CI) ‐0.39 [‐0.45, ‐0.33]
23.4 Lente‐ total episodes 1 132 Mean Difference (IV, Fixed, 95% CI) 0.49 [‐0.36, 1.34]
23.5 Lente‐ severe episodes 1 132 Mean Difference (IV, Fixed, 95% CI) 0.98 [0.66, 1.30]
23.6 Lente‐ nocturnal episodes 1 12 Mean Difference (IV, Fixed, 95% CI) ‐2.97 [‐4.49, ‐1.45]
24 Glycated haemoglobin‐ short acting type 22 6666 Mean Difference (IV, Fixed, 95% CI) ‐0.08 [‐0.12, ‐0.04]
24.1 Porcine insulin 1 12 Mean Difference (IV, Fixed, 95% CI) ‐0.10 [‐1.75, 1.55]
24.2 Human insulin versus insulin analogues 3 757 Mean Difference (IV, Fixed, 95% CI) ‐0.29 [‐0.41, ‐0.17]
24.3 Human insulin 7 2936 Mean Difference (IV, Fixed, 95% CI) 0.03 [‐0.04, 0.09]
24.4 Insulin analogues 11 2961 Mean Difference (IV, Fixed, 95% CI) ‐0.13 [‐0.20, ‐0.06]
25 Fasting blood glucose‐total‐ short acting type 17 5409 Mean Difference (IV, Fixed, 95% CI) ‐0.86 [1.00, ‐0.72]
25.1 Human insulin 8 3054 Mean Difference (IV, Fixed, 95% CI) ‐0.75 [‐0.92, ‐0.58]
25.2 Insulin analogues 6 2181 Mean Difference (IV, Fixed, 95% CI) ‐0.96 [‐1.22, ‐0.70]
25.3 Porcine insulin 1 12 Mean Difference (IV, Fixed, 95% CI) ‐4.8 [‐7.78, ‐1.82]
25.4 Human insulin versus insulin analogues 2 162 Mean Difference (IV, Fixed, 95% CI) ‐1.26 [‐1.75, ‐0.77]
26 Fasting plasma glucose‐ total‐ short acting type 11 4868 Mean Difference (IV, Fixed, 95% CI) ‐0.63 [‐0.86, ‐0.40]
26.1 Human insulin 5 2455 Mean Difference (IV, Fixed, 95% CI) ‐1.13 [‐1.54, ‐0.72]
26.2 Insulin analogues 4 1768 Mean Difference (IV, Fixed, 95% CI) ‐1.62 [‐2.14, ‐1.11]
26.3 Human insulin versus insulin analogues 2 645 Mean Difference (IV, Fixed, 95% CI) 0.07 [‐0.26, 0.39]
27 Mean daily self measured blood glucose (SMBG) average (7‐8 points)‐ short acting type 6 790 Mean Difference (IV, Fixed, 95% CI) ‐0.47 [‐0.58, ‐0.36]
27.1 Human insulin 3 506 Mean Difference (IV, Fixed, 95% CI) 0.15 [‐0.26, 0.56]
27.2 Insulin analogues 2 172 Mean Difference (IV, Fixed, 95% CI) ‐0.5 [‐0.61, ‐0.39]
27.3 Human insulin versus insulin analogues 1 112 Mean Difference (IV, Fixed, 95% CI) ‐1.90 [‐3.01, ‐0.79]
28 Percent of participating experiencing hypoglycemia‐ short acting type 20   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
28.1 Human insulin versus insulin analogues‐ severe episodes 3 757 Odds Ratio (M‐H, Fixed, 95% CI) 0.96 [0.57, 1.62]
28.2 Human insulin versus insulin analogues‐ nocturnal episodes 2 707 Odds Ratio (M‐H, Fixed, 95% CI) 0.46 [0.34, 0.63]
28.3 Human insulin‐ total episodes 7 2925 Odds Ratio (M‐H, Fixed, 95% CI) 0.98 [0.80, 1.19]
28.4 Human insulin‐ severe episodes 6 2669 Odds Ratio (M‐H, Fixed, 95% CI) 0.68 [0.52, 0.89]
28.5 Human insulin‐ nocturnal episodes 5 2821 Odds Ratio (M‐H, Fixed, 95% CI) 0.87 [0.74, 1.03]
28.6 Insulin analogues‐ total episodes 10 3953 Odds Ratio (M‐H, Fixed, 95% CI) 0.91 [0.74, 1.14]
28.7 Insulin analogues‐ severe episodes 8 2401 Odds Ratio (M‐H, Fixed, 95% CI) 0.72 [0.54, 0.96]
28.8 Insulin analogues‐ nocturnal episodes 7 2497 Odds Ratio (M‐H, Fixed, 95% CI) 0.75 [0.63, 0.90]
29 Number of serious adverse events‐ short acting type 14 4878 Odds Ratio (M‐H, Fixed, 95% CI) 0.89 [0.66, 1.21]
29.1 Human insulin 7 2925 Odds Ratio (M‐H, Fixed, 95% CI) 0.73 [0.49, 1.09]
29.2 Insulin analogues 4 1196 Odds Ratio (M‐H, Fixed, 95% CI) 1.18 [0.64, 2.17]
29.3 Human insulin versus insulin analogues 3 757 Odds Ratio (M‐H, Fixed, 95% CI) 1.16 [0.54, 2.51]
30 Hypoglycemic events per 100 patient's days‐ short acting type 18   Mean Difference (IV, Fixed, 95% CI) Subtotals only
30.1 Human insulin‐ total episodes 4 1531 Mean Difference (IV, Fixed, 95% CI) ‐0.42 [‐0.56, ‐0.28]
30.2 Human insulin‐ severe episodes 4 1531 Mean Difference (IV, Fixed, 95% CI) ‐0.01 [‐0.03, 0.02]
30.3 Human insulin‐ nocturnal episodes 3 1399 Mean Difference (IV, Fixed, 95% CI) ‐0.17 [‐0.25, ‐0.10]
30.4 Insulin analogues‐ total episodes 8 2416 Mean Difference (IV, Fixed, 95% CI) ‐2.07 [‐2.38, ‐1.75]
30.5 Insulin analogues‐ severe episodes 9 2388 Mean Difference (IV, Fixed, 95% CI) 0.01 [‐0.01, 0.04]
30.6 Insulin analogues‐ nocturnal episodes 10 2803 Mean Difference (IV, Fixed, 95% CI) ‐0.63 [‐0.74, ‐0.52]
30.7 Human insulin versus insulin analogues‐ total episodes 3 757 Mean Difference (IV, Fixed, 95% CI) ‐1.61 [‐2.02, ‐1.19]
30.8 Human insulin versus insulin analogues‐ severe episodes 2 645 Mean Difference (IV, Fixed, 95% CI) ‐0.02 [‐0.07, 0.03]
30.9 Human insulin versus insulin analogues‐ nocturnal episodes 3 757 Mean Difference (IV, Fixed, 95% CI) ‐0.94 [‐1.10, ‐0.77]
31 Glycated haemoglobin‐ number of basal doses (long acting) 22 6666 Mean Difference (IV, Fixed, 95% CI) ‐0.08 [‐0.12, ‐0.04]
31.1 Once daily 13 3996 Mean Difference (IV, Fixed, 95% CI) ‐0.07 [‐0.13, ‐0.02]
31.2 Twice or more daily 7 2145 Mean Difference (IV, Fixed, 95% CI) ‐0.13 [‐0.21, ‐0.05]
31.3 According to glucose control 2 525 Mean Difference (IV, Fixed, 95% CI) 0.10 [‐0.10, 0.30]
32 Fasting blood glucose‐total‐ number of basal doses (long acting) 17 5409 Mean Difference (IV, Fixed, 95% CI) ‐0.86 [1.00, ‐0.72]
32.1 Once daily 11 3828 Mean Difference (IV, Fixed, 95% CI) ‐0.83 [‐0.98, ‐0.68]
32.2 Twice or more daily 5 1234 Mean Difference (IV, Fixed, 95% CI) ‐0.99 [‐1.38, ‐0.60]
32.3 According to glucose control 1 347 Mean Difference (IV, Fixed, 95% CI) ‐1.20 [‐2.18, ‐0.22]
33 Fasting plasma glucose‐ total‐ number of basal doses (long acting) 11 4868 Mean Difference (IV, Fixed, 95% CI) ‐0.63 [‐0.86, ‐0.40]
33.1 Once daily 7 3124 Mean Difference (IV, Fixed, 95% CI) ‐0.54 [‐0.81, ‐0.27]
33.2 Twice or more daily 4 1744 Mean Difference (IV, Fixed, 95% CI) ‐0.87 [‐1.31, ‐0.43]
34 Mean daily self measured blood glucose (SMBG) average (7‐8 points)‐ number of basal doses (long acting) 6 790 Mean Difference (IV, Fixed, 95% CI) ‐0.47 [‐0.58, ‐0.36]
34.1 Once daily 4 607 Mean Difference (IV, Fixed, 95% CI) ‐0.35 [‐0.67, ‐0.03]
34.2 Twice or more daily 2 183 Mean Difference (IV, Fixed, 95% CI) ‐0.48 [‐0.60, ‐0.37]
35 Percent of participating experiencing hypoglycemia‐ number of basal doses (long acting) 20   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
35.1 Once daily‐ total episodes 10 3783 Odds Ratio (M‐H, Fixed, 95% CI) 1.01 [0.84, 1.21]
35.2 Once daily‐ severe episodes 12 3736 Odds Ratio (M‐H, Fixed, 95% CI) 0.74 [0.59, 0.94]
35.3 Once daily‐ nocturnal episodes 7 3058 Odds Ratio (M‐H, Fixed, 95% CI) 0.86 [0.73, 1.00]
35.4 Twice or more daily‐ total episodes 5 2001 Odds Ratio (M‐H, Fixed, 95% CI) 0.78 [0.58, 1.04]
35.5 Twice or more daily‐ severe episodes 5 2491 Odds Ratio (M‐H, Fixed, 95% CI) 0.69 [0.52, 0.93]
35.6 Twice or more daily‐ nocturnal episodes 4 1576 Odds Ratio (M‐H, Fixed, 95% CI) 0.53 [0.42, 0.65]
35.7 According to glucose control‐ total episodes 1 347 Odds Ratio (M‐H, Fixed, 95% CI) 0.44 [0.09, 2.06]
35.8 According to glucose control‐ severe episodes 1 347 Odds Ratio (M‐H, Fixed, 95% CI) 0.76 [0.43, 1.35]
35.9 According to glucose control‐ severe episodes 1 347 Odds Ratio (M‐H, Fixed, 95% CI) 0.42 [0.22, 0.78]
36 Number of serious adverse events‐ number of basal doses (long acting) 15 5303 Odds Ratio (M‐H, Fixed, 95% CI) 0.81 [0.63, 1.04]
36.1 Once daily 10 3212 Odds Ratio (M‐H, Fixed, 95% CI) 0.75 [0.52, 1.09]
36.2 Twice or more daily 4 1744 Odds Ratio (M‐H, Fixed, 95% CI) 0.86 [0.60, 1.23]
36.3 ACcording to glucose control 1 347 Odds Ratio (M‐H, Fixed, 95% CI) 0.99 [0.18, 5.49]
37 Hypoglycemic events per 100 patient's days‐ number of basal doses (long acting) 19   Mean Difference (IV, Fixed, 95% CI) Subtotals only
37.1 Once daily‐ total episodes 9 2540 Mean Difference (IV, Fixed, 95% CI) ‐0.45 [‐0.58, ‐0.31]
37.2 Once daily‐ severe episodes 9 2479 Mean Difference (IV, Fixed, 95% CI) ‐0.00 [‐0.02, 0.02]
37.3 Once daily‐ nocturnal episodes 10 2611 Mean Difference (IV, Fixed, 95% CI) ‐0.20 [‐0.26, ‐0.13]
37.4 Twice or more daily‐ total episodes 5 1817 Mean Difference (IV, Fixed, 95% CI) ‐2.22 [‐2.51, ‐1.92]
37.5 Twice or more daily‐ severe episodes 4 1560 Mean Difference (IV, Fixed, 95% CI) 0.00 [‐0.04, 0.04]
37.6 Twice or more daily‐ nocturnal episodes 6 2013 Mean Difference (IV, Fixed, 95% CI) ‐0.97 [‐1.09, ‐0.85]
37.7 According to glucose control‐ total episodes 1 347 Mean Difference (IV, Fixed, 95% CI) ‐3.30 [‐4.53, ‐2.07]
37.8 According to glucose control‐ severe episodes 2 525 Mean Difference (IV, Fixed, 95% CI) 0.02 [‐0.07, 0.12]
37.9 According to glucose control‐ nocturnal episodes 1 347 Mean Difference (IV, Fixed, 95% CI) ‐1.11 [‐1.58, ‐0.64]
38 Glycated haemoglobin‐ number of basal doses (intermediate acting) 22 6666 Mean Difference (IV, Fixed, 95% CI) ‐0.08 [‐0.12, ‐0.04]
38.1 Once daily 3 922 Mean Difference (IV, Fixed, 95% CI) ‐0.15 [‐0.32, 0.03]
38.2 Twice or more daily 10 2431 Mean Difference (IV, Fixed, 95% CI) ‐0.19 [‐0.25, ‐0.12]
38.3 According to glucose control 9 3313 Mean Difference (IV, Fixed, 95% CI) 0.01 [‐0.05, 0.07]
39 Fasting blood glucose‐total‐ number of basal doses (intermediate acting) 17 5409 Mean Difference (IV, Fixed, 95% CI) ‐0.86 [1.00, ‐0.72]
39.1 Once daily 4 1040 Mean Difference (IV, Fixed, 95% CI) ‐0.97 [‐1.26, ‐0.68]
39.2 Twice or more daily 5 1234 Mean Difference (IV, Fixed, 95% CI) ‐0.99 [‐1.38, ‐0.60]
39.3 According to glucose control 8 3135 Mean Difference (IV, Fixed, 95% CI) ‐0.79 [‐0.96, ‐0.62]
40 Fasting plasma glucose‐ total‐ number of basal doses (intermediate acting) 11 4868 Mean Difference (IV, Fixed, 95% CI) ‐0.63 [‐0.86, ‐0.40]
40.1 Once daily 2 797 Mean Difference (IV, Fixed, 95% CI) 0.03 [‐0.32, 0.38]
40.2 Twice or more daily 4 1744 Mean Difference (IV, Fixed, 95% CI) ‐0.87 [‐1.31, ‐0.43]
40.3 According to glucose control 5 2327 Mean Difference (IV, Fixed, 95% CI) ‐1.32 [‐1.73, ‐0.91]
41 Mean daily self measured blood glucose (SMBG) average (7‐8 points)‐ number of basal doses (intermediate acting 6 790 Mean Difference (IV, Fixed, 95% CI) ‐0.47 [‐0.58, ‐0.36]
41.1 Once daily 1 118 Mean Difference (IV, Fixed, 95% CI) ‐0.10 [‐0.73, 0.53]
41.2 Twice or more daily 3 304 Mean Difference (IV, Fixed, 95% CI) ‐0.48 [‐0.60, ‐0.37]
41.3 According to blood glucose 2 368 Mean Difference (IV, Fixed, 95% CI) ‐0.35 [‐0.95, 0.25]
42 Percent of participating experiencing hypoglycemia‐ number of basal doses (intermediate acting) 20   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
42.1 Once daily‐ total episodes 3 990 Odds Ratio (M‐H, Fixed, 95% CI) 1.42 [0.90, 2.22]
42.2 Once daily‐ severe episodes 3 915 Odds Ratio (M‐H, Fixed, 95% CI) 0.68 [0.41, 1.15]
42.3 Once daily‐ nocturnal episodes 2 872 Odds Ratio (M‐H, Fixed, 95% CI) 0.91 [0.67, 1.24]
42.4 Twice or more daily‐ total episodes 6 2115 Odds Ratio (M‐H, Fixed, 95% CI) 0.81 [0.61, 1.07]
42.5 Twice or more daily‐ severe episodes 7 2030 Odds Ratio (M‐H, Fixed, 95% CI) 0.69 [0.50, 0.96]
42.6 Twice or more daily‐ nocturnal episodes 4 1744 Odds Ratio (M‐H, Fixed, 95% CI) 0.55 [0.45, 0.69]
42.7 According to blood glucose‐ total episodes 7 3026 Odds Ratio (M‐H, Fixed, 95% CI) 0.92 [0.75, 1.12]
42.8 According to blood glucose‐ severe episodes 7 2882 Odds Ratio (M‐H, Fixed, 95% CI) 0.76 [0.59, 0.96]
42.9 According to blood glucose‐ nocturnal episodes 7 2790 Odds Ratio (M‐H, Fixed, 95% CI) 0.76 [0.64, 0.89]
43 Number of serious adverse events‐ number of basal doses (intermediate acting) 14 4878 Odds Ratio (M‐H, Fixed, 95% CI) 0.89 [0.66, 1.21]
43.1 Once daily 4 1040 Odds Ratio (M‐H, Fixed, 95% CI) 1.24 [0.56, 2.74]
43.2 Twice or more daily 3 1319 Odds Ratio (M‐H, Fixed, 95% CI) 1.31 [0.74, 2.33]
43.3 According to glucose control 7 2519 Odds Ratio (M‐H, Fixed, 95% CI) 0.67 [0.44, 1.00]
44 Hypoglycemic events per 100 patient's days‐ number of basal doses (intermediate acting) 19   Mean Difference (IV, Fixed, 95% CI) Subtotals only
44.1 Once daily‐ total episodes 4 1040 Mean Difference (IV, Fixed, 95% CI) ‐0.49 [‐0.97, ‐0.01]
44.2 Once daily‐ severe episodes 4 1040 Mean Difference (IV, Fixed, 95% CI) ‐0.00 [‐0.05, 0.04]
44.3 Once daily‐ nocturnal episodes 4 1040 Mean Difference (IV, Fixed, 95% CI) ‐0.60 [‐0.79, ‐0.41]
44.4 Twice or more daily‐ total episodes 7 2052 Mean Difference (IV, Fixed, 95% CI) ‐2.30 [‐2.58, ‐2.03]
44.5 Twice or more daily‐ severe episodes 7 1846 Mean Difference (IV, Fixed, 95% CI) 0.00 [‐0.03, 0.03]
44.6 Twice or more daily‐ nocturnal episodes 9 2319 Mean Difference (IV, Fixed, 95% CI) ‐0.86 [‐0.97, ‐0.76]
44.7 According to glucose control‐ total episodes 4 1612 Mean Difference (IV, Fixed, 95% CI) ‐0.40 [‐0.54, ‐0.26]
44.8 According to glucose control‐ severe episodes 4 1678 Mean Difference (IV, Fixed, 95% CI) ‐0.00 [‐0.02, 0.02]
44.9 According to glucose control‐ nocturnal episodes 4 1612 Mean Difference (IV, Fixed, 95% CI) ‐0.12 [‐0.19, ‐0.04]
45 Glycated haemoglobin‐ diabetes status 21 6633 Mean Difference (IV, Fixed, 95% CI) ‐0.08 [‐0.13, ‐0.04]
45.1 Fare 6 2167 Mean Difference (IV, Fixed, 95% CI) ‐0.04 [‐0.11, 0.03]
45.2 Intermediate 14 4138 Mean Difference (IV, Fixed, 95% CI) ‐0.11 [‐0.17, ‐0.05]
45.3 Poor 2 328 Mean Difference (IV, Fixed, 95% CI) ‐0.06 [‐0.38, 0.25]
46 Fasting blood glucose‐total‐ diabetes status 16 5060 Mean Difference (IV, Fixed, 95% CI) ‐0.77 [‐0.91, ‐0.63]
46.1 Fare 4 1856 Mean Difference (IV, Fixed, 95% CI) ‐0.48 [‐0.69, ‐0.28]
46.2 Intermediate 11 3192 Mean Difference (IV, Fixed, 95% CI) ‐1.01 [‐1.21, ‐0.81]
46.3 Poor 1 12 Mean Difference (IV, Fixed, 95% CI) ‐4.8 [‐7.78, ‐1.82]
47 Fasting plasma glucose‐ total‐ diabetes status 11 4868 Mean Difference (IV, Fixed, 95% CI) ‐0.63 [‐0.86, ‐0.40]
47.1 Fare 3 1738 Mean Difference (IV, Fixed, 95% CI) ‐1.07 [‐1.56, ‐0.58]
47.2 Intermediate 7 2814 Mean Difference (IV, Fixed, 95% CI) ‐0.51 [‐0.76, ‐0.25]
47.3 Poor 1 316 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
48 Mean daily self measured blood glucose (SMBG) average (7‐8 points)‐ diabetes status 6 790 Mean Difference (IV, Fixed, 95% CI) ‐0.47 [‐0.58, ‐0.36]
48.1 Fare 3 290 Mean Difference (IV, Fixed, 95% CI) ‐0.49 [‐0.60, ‐0.38]
48.2 Intermediate 3 500 Mean Difference (IV, Fixed, 95% CI) ‐0.09 [‐0.58, 0.40]
49 Percent of participating experiencing hypoglycemia‐ diabetes status 19   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
49.1 Fare‐ total episodes 5 2113 Odds Ratio (M‐H, Fixed, 95% CI) 0.94 [0.75, 1.19]
49.2 Fare‐ severe episodes 6 2028 Odds Ratio (M‐H, Fixed, 95% CI) 0.69 [0.49, 0.98]
49.3 Fare‐ nocturnal episodes 4 1995 Odds Ratio (M‐H, Fixed, 95% CI) 0.88 [0.73, 1.07]
49.4 Intermediate‐ total episodes 9 3353 Odds Ratio (M‐H, Fixed, 95% CI) 0.90 [0.72, 1.13]
49.5 Intermediate‐ severe episodes 9 3134 Odds Ratio (M‐H, Fixed, 95% CI) 0.77 [0.59, 0.99]
49.6 Intermediate‐ nocturnal episodes 8 3095 Odds Ratio (M‐H, Fixed, 95% CI) 0.60 [0.51, 0.70]
49.7 Poor‐ total episodes 1 316 Odds Ratio (M‐H, Fixed, 95% CI) 0.97 [0.29, 3.24]
49.8 Poor‐ severe episodes 1 316 Odds Ratio (M‐H, Fixed, 95% CI) 0.60 [0.32, 1.10]
49.9 Poor‐ nocturnal episodes 1 316 Odds Ratio (M‐H, Fixed, 95% CI) 0.67 [0.33, 1.35]
50 Number of serious adverse events‐ diabetes status 13 4529 Odds Ratio (M‐H, Fixed, 95% CI) 1.06 [0.76, 1.49]
50.1 Fare 3 1237 Odds Ratio (M‐H, Fixed, 95% CI) 0.97 [0.57, 1.64]
50.2 Intermediate 9 2976 Odds Ratio (M‐H, Fixed, 95% CI) 1.25 [0.76, 2.04]
50.3 Poor 1 316 Odds Ratio (M‐H, Fixed, 95% CI) 0.77 [0.29, 2.02]
51 Hypoglycemic events per 100 patient's days‐ diabetes status 19   Mean Difference (IV, Fixed, 95% CI) Subtotals only
51.1 Fare‐ total episodes 5 1649 Mean Difference (IV, Fixed, 95% CI) ‐0.55 [‐0.69, ‐0.41]
51.2 Fare‐ severe episodes 5 1443 Mean Difference (IV, Fixed, 95% CI) ‐0.01 [‐0.03, 0.02]
51.3 Fare‐ nocturnal episodes 6 1720 Mean Difference (IV, Fixed, 95% CI) ‐0.19 [‐0.26, ‐0.12]
51.4 Intermediate‐ total episodes 10 3055 Mean Difference (IV, Fixed, 95% CI) ‐1.46 [‐1.71, ‐1.22]
51.5 Intermediate‐ severe episodes 10 3121 Mean Difference (IV, Fixed, 95% CI) 0.00 [‐0.02, 0.03]
51.6 Intermediate‐ nocturnal episodes 9 2923 Mean Difference (IV, Fixed, 95% CI) ‐0.69 [‐0.78, ‐0.59]
51.7 Poor‐ nocturnal episodes 2 328 Mean Difference (IV, Fixed, 95% CI) ‐1.80 [‐2.29, ‐1.32]